Abstract
Glucose, insulin and non-esterified fatty acid (NEFA) metabolism was studied in 18 patients (mean age 49) with ischemic heart disease (IHD) who did not have any concurrent disorder known to affect glucose tolerance.
Significant hyperglycemia and hyperinsulinemia were observed in the IHD patients after oral glucose. The serum NEFA declined to a lower level in IHD patients than in normal subjects who received glucose.
In response to hypoglycemia following the oral administration of sodium tolbutamide the serum NEFA in IHD patients rose to a higher level in the rebound phase than in normal subjects. This rise was preceded by a sharp decline in the concentration of circulating insulin.
In 72% of the patients (IHD sub-group) the blood glucose values after oral glucose satisfied the criteria for the diagnosis of diabetes mellitus. The metabolic changes following oral glucose in the IHD sub-group and in asymptomatic diabetics (AD), free of clinical atherosclerosis and with similar impairment in glucose tolerance, were compared. Despite insignificantly lower insulin concentrations, the AD showed a significantly lesser fall in circulating NEFA than did the patients in the IHD sub-group. After oral sodium tolbutamide the IHD sub-group patients showed a greater insulin response and a greater rebound increase in circulating NEFA than did the AD.
These differences in response to oral glucose and to sodium tolbutamide suggest that the pathogenesis of the impaired glucose tolerance in IHD may be different from that responsible for abnormal carbohydrate tolerance in asymptomatic diabetics without evident atherosclerosis. The abnormalities demonstrated in glucose, insulin and NEFA metabolism may play a role in the genesis of the hyperlipoproteinemia and atherosclerosis of IHD. One possible mechanism leading to hyperlipoproteinemia in ischemic heart disease compatible with the data is discussed.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- DOLE V. P., MEINERTZ H. Microdetermination of long-chain fatty acids in plasma and tissues. J Biol Chem. 1960 Sep;235:2595–2599. [PubMed] [Google Scholar]
- FRIEDBERG S. J., KLEIN R. F., TROUT D. L., BOGDONOFF M. D., ESTES E. H., Jr The incorporation of plasma free fatty acids into plasma triglycerides in man. J Clin Invest. 1961 Oct;40:1846–1855. doi: 10.1172/JCI104409. [DOI] [PMC free article] [PubMed] [Google Scholar]
- JEANRENAUD B., RENOLD A. E. Studies on rat adipose tissue in vitro. 7. Effects of adrenal cortical hormones. J Biol Chem. 1960 Aug;235:2217–2223. [PubMed] [Google Scholar]
- Porte D., Jr, Graber A. L., Kuzuya T., Williams R. H. The effect of epinephrine on immunoreactive insulin levels in man. J Clin Invest. 1966 Feb;45(2):228–236. doi: 10.1172/JCI105335. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Porte D., Jr, Williams R. H. Inhibition of insulin release by norepinephrine in man. Science. 1966 May 27;152(3726):1248–1250. doi: 10.1126/science.152.3726.1248. [DOI] [PubMed] [Google Scholar]
- RUDMAN D. THE ADIPOKINETIC ACTION OF POLYPEPTIDE AND AMINE HORMONES UPON THE ADIPOSE TISSUE OF VARIOUS ANIMAL SPECIES. J Lipid Res. 1963 Apr;4:119–129. [PubMed] [Google Scholar]
- Soeldner J. S., Slone D. Critical variables in the radioimmunoassay of serum insulin using the double antibody technic. Diabetes. 1965 Dec;14(12):771–779. doi: 10.2337/diab.14.12.771. [DOI] [PubMed] [Google Scholar]